

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the recent development about the Group.

1. Appointment of Chief Scientist

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that Dr. Liu Xiaohua (“**Dr. Liu**”), an artificial intelligence (“**AI**”) expert, has been appointed as the Chief Scientist of the Company. Dr. Liu has been working in the field of AI technology research for more than 15 years and is among the first batch of AI specialists to have applied AI to Big Data in the medical field. He served as a scientist and held senior management positions in Microsoft Research Asia, Amazon.com, Inc., Huawei Noah’s Ark Lab and Meta Platforms, Inc. (formerly known as Facebook, Inc.). He is well-versed in natural language processing, deep learning and knowledge graph technology.

The Company consistently attaches great importance to research and development and believes that Dr. Liu’s outstanding research capabilities and extensive experience in the development and application of AI technology will bring great value to the Company.

2. Business Development

(a) Cloud GPT

The Board is pleased to announce the launch of Cloud GPT, an intelligent diagnostics technology powered by ClouDr Machine Learning Infrastructure and formed part of the ClouDr Brain. After extensive and specialized training in medical data, Cloud GPT is able to deal with complex and multi-modal situations. So far, the Company has applied Cloud GPT in software-as-a-service (SaaS) installations in hospitals and in online hospitals with a focus on clinical decision supporting system (CDSS). As a hospital SaaS, Cloud GPT analyzes patients' conditions holistically, provides early warnings and suggestions for treatment plans of similar diseases and assists doctors in giving faster and more accurate diagnosis and treatment plans. In its application in online hospitals, Cloud GPT assists doctors and pharmacists in providing prescription quality control and improves the efficiency and accuracy of the doctors' diagnosis and treatment plans.

(b) Cloud DTx Platform and ClouDTx-CVD

The Board is pleased to announce that its Cloud DTx Platform, powered by ClouDr Machine Learning Infrastructure and formed another part of the ClouDr Brain, has been applied to AI-assisted drug and device research and development, providing several key technical solutions for digital medical care for chronic diseases. The digital therapy of *ClouDTx-CVD* has also been successfully developed for treating cardiovascular diseases. From the research results published in the Journal of Medical Internet Research (JMIR) on April 12, 2023, a multicenter clinical study found that after being in the digital therapy of *ClouDTx-CVD* for six months, the low-density lipoprotein C (LDL-C) levels of patients with cardiovascular diseases in the digital therapy treatment group decreased by 10%, compared with the control group ($P < 0.05$), and the LDL-C normality rate was significantly higher than that of the control group ($P < 0.05$). This is the first clinical study on the use of digital therapy to intervene blood lipids in cardiovascular disease treatment and proves that digital therapy is an effective complement to existing clinical treatment options for patients with cardiovascular diseases.

The research and development of the technologies discussed above was funded by internal resources of the Group.

The Board believes that the application of AI technologies to the Company's services and the development of digital therapy are in line with the Group's vision to lead China's digital chronic condition management market through our solutions. These latest initiatives are important steps taken by the Company to identify more business opportunities and profit potential for the Group to maximize returns to our shareholders.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, May 11, 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*